Biotherapeutics and Business University College Dublin

Overview

The Biotherapeutics and Business M.Sc. at University College Dublin provides a multidisciplinary education that combines advanced drug development with high-level business strategy. This programme is designed to equip students with the technical knowledge and commercial acumen required to navigate the complex biopharmaceutical landscape. By integrating science and management, the curriculum prepares graduates to lead innovation in local and international settings.

Why Biotherapeutics and Business at University College Dublin?

This programme offers a unique global perspective, featuring contributions from a diverse range of international academics and industry experts. Students benefit from a dynamic learning environment where they share practical experiences with peers from various professional backgrounds. The curriculum is specifically developed in consultation with major employers to ensure that the skills taught are directly applicable to current industry demands and technological advancements.

Tuition Fee Breakdown

• International fee: EUR 29100 per year
• European fee: EUR 16400 per year

Visit the Fees and Funding section for a breakdown in your local currency.

Syllabus

The curriculum covers both the scientific pipeline of drug discovery and core business management principles. Modules may include:

• Professional Career Development
• Business of Biotechnology and Science
• Marketing Management
• Biotherapeutic Pipeline
• Business Strategy
• Organisational Behaviour
• Corporate Finance
• Systems Biology in Drug Dev
• Feasibility and Business Plan

Careers with Biotherapeutics and Business

Graduates are prepared for diverse roles within the biopharmaceutical and life sciences sectors, ranging from research management to business development. The programme includes the creation of a business development plan, which helps students build vital connections with prospective employers. This practical approach enhances employability in various commercial and scientific functions.

Former students and graduates have found opportunities with leading global organisations. Potential employers include industry giants such as:

• Abbott and Allergan
• Amgen and Baxter Healthcare
• Eli Lilly and Co.
• GSK and Janssen Pharmaceutical Ltd.
• Johnson & Johnson Ltd.
• MSD and Sandoz
• Icon Clinical Research

The degree is highly valued by companies involved in clinical research, drug entity valuation, and the commercialisation of novel biotechnological solutions. Graduates often pursue careers as scientists, entrepreneurs, or consultants within the international biotherapeutics industry.